Antiviral Drugs - Americas

Americas

The projected revenue in the Antiviral Drugs market for the Americas is estimated to reach US$33.19bn by 2024.
This market is expected to exhibit a compound annual growth rate (CAGR) of 1.39% during the period of 2024-2029, leading to a market volume of US$35.56bn by 2029.
When compared globally, United States is anticipated to generate the highest revenue, amounting to US$30,640.00m in 2024.
In the Americas, the market for antiviral drugs is witnessing a surge in demand due to the prevalence of viral diseases.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Antiviral Drugs market in Americas has been growing steadily in recent years, driven by a number of factors such as increasing prevalence of viral infections, rising awareness about antiviral drugs, and growing demand for effective treatments.

Customer preferences: Customers in the Americas are increasingly looking for antiviral drugs that are effective, safe, and affordable. They are also more likely to choose drugs that are easy to administer and have minimal side effects. In addition, there is a growing preference for combination therapies that target multiple viruses at once.

Trends in the market: One of the major trends in the Antiviral Drugs market in Americas is the increasing use of generic drugs. This is due to the expiration of patents on several major antiviral drugs, which has led to the entry of generic versions into the market. As a result, customers are able to access more affordable treatments.Another trend in the market is the growing focus on research and development of new antiviral drugs. With the increasing prevalence of viral infections, there is a need for more effective treatments that can target a wider range of viruses. This has led to the development of new antiviral drugs that are more potent and have fewer side effects.

Local special circumstances: In the United States, there is a significant focus on the development of antiviral drugs for the treatment of HIV/AIDS. This is due to the high prevalence of the disease in the country, as well as the significant investment in research and development of new treatments.In Latin America, there is a growing demand for antiviral drugs to treat diseases such as dengue fever, Zika virus, and Chikungunya virus. These diseases are endemic in the region, and there is a need for more effective treatments to address the growing public health concerns.

Underlying macroeconomic factors: The Antiviral Drugs market in Americas is also influenced by a number of macroeconomic factors such as government policies, healthcare infrastructure, and funding for research and development. In countries with strong healthcare systems and government support for research and development, there is a greater focus on the development of new antiviral drugs and access to affordable treatments. In countries with weaker healthcare systems, the market for antiviral drugs may be more limited, and customers may have less access to effective treatments.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.